Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers.
Journal: Journal of medicinal chemistry
Published: February 21, 2026
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity.
Journal: bioRxiv : the preprint server for biology
Published: August 30, 2024
Showing 1-2 of 2
Last Updated: 09/26/2026